AURA
NASD Aura Biosciences Inc$6.38 ↓ -0.13 (-1.92%) Trading Down from the previous close of $6.51
- YTD change
- +17.06%
- vs 20-day SMA
- -0.10%
- vs 200-day SMA
- -3.98%
Price ranges
Price & Performance
-0.28 (-4.06%) / 6M
Signals & Sentiment
Momentum, market sentiment, and recent alerts
- The stock is 75.6% away from all-time highs of $26.16
- AURA is up 17% since the beginning of the year
- AURA is up 6% over the past 12 months
- AURA is down 9% over the past 1 month
- 7% of all AURA investors are betting against AURA
AURA reads not so good: price sits below both the 20- and 200-day averages, the 12-month move is +7.9%.
- Previous minute
- +$0.00
- Last hour
- -$0.05
- Last 5 days
- +5.63%
- vs 8-day SMA
- +2.25%
Financial Strength
Earnings, valuation, and balance sheet
Earnings
Valuation
Balance sheet & scale
Company & Peers
Company profile and competitor comparison
Company profile
Aura Biosciences, Inc. is a clinical-stage oncology company, which engages in developing a novel technology platform based on virus-like drug conjugates (VDCs) to target and destroy cancer cells selectively while activating the immune system to create long lasting anti-tumor immunity. The firm's product candidate belzupacap sarotalocan (AU-011) is in Phase 2 development for the first line treatment of choroidal melanoma, a vision and life-threatening form of eye cancer where standard of care radioactive treatments leave patients with major vision loss and severe comorbidities. The was founded by Elisabet de los Pinos in 2007 and is headquartered in Boston, MA.
You looked up one stock
Trade Ideas watches them all
Real-time scanning and AI-generated signals across the entire market.
Prices and alerts are delayed by at least 20 minutes. Chart history reflects daily closing prices. Information is provided for research purposes only and is not investment advice.
